FDA Tightens Restrictions On Sanofi's Multaq
The U.S. Food and Drug Administration on Monday revised its label for Sanofi SA's heart rhythm drug Multaq, saying a safety review showed the drug could increase the risk of death...To view the full article, register now.
Already a subscriber? Click here to view full article